Considering the role of FLT3 in AML, we evaluated the response of six representative AML cell lines with different genotypes at the FLT3 locus to the treatment with p300/CBP inhibitors A485 or CCS1477. This evidence concerns the gene CREBBP and acute myeloid leukemia.